{
  "id": 7712,
  "url": "https://doi.org/10.1371/journal.pone.0142190",
  "title": "Tumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab Therapy",
  "summary": "BACKGROUND: Bevacizumab is an exogenous inhibitor which inhibits the biological activity of human VEGF. Several studies have investigated the effectiveness of bevacizumab therapy according to different cancer types but these days there is an intense debate on its utility. We have investigated different methods to find the best tumor volume estimation since it creates the possibility for precise and effective drug administration with a much lower dose than in the protocol. MATERIALS AND METHODS: ",
  "authors": "Johanna Sápi, Levente Kovács, Dániel András Drexler, Pál Kocsis, Dávid Gajári, Zoltàn Sápi",
  "category": "research",
  "topics": "healthcare,finance-investment,biotech",
  "orgs": null,
  "regions": null,
  "published_at": "2015-11-05T00:00:00.000Z",
  "fetched_at": "2026-07-14T16:33:27.486Z",
  "source_slug": "openalex",
  "source_name": "OpenAlex",
  "source_homepage": "https://openalex.org",
  "ethics_ai_record_url": "https://ethics.ai/record/7712",
  "original_url": "https://doi.org/10.1371/journal.pone.0142190",
  "evidence_status": "source-only",
  "attribution": "via ethics.ai"
}